SyrSpend® SF PH4 Stability

A new peer-reviewed study has been published by the International Journal of Pharmaceutical Compouding highlighting the stability of 10 commonly used active pharmaceutical ingredients in Fagron's SyrSpend® SF PH4 vehicle. SyrSpend® SF PH4 (liquid) is a ready-to-use, all-in-one suspending and sweetening oral liquid vehicle that can be used for compounding and as an administration aid. The product allows for more a convenient method for preparation of suspensions which provides pharmaceutical stability and consistency.

The study investigates the stability of the suspended pharmaceutical ingredients at both controlled refrigeration temperature (2°C to 8°C) and controlled room temperature (20°C to 25°C). The stability of each suspension was verified by high-performance liquid chromotography to measure the quantity of the active pharmaceutical ingredient remaining over a certain period of the time. It was concluded that the suspensions had reached beyond-use-date past 90 days to suggest that SyrSpend® SF PH4 is stable when used with the different pharmacological classes of active pharmaceutical ingredients.

Alprazolam 1 mg/ml in SyrSpend® SF PH4 (liquid)
Atropine sulfate 0.1 mg/ml in SyrSpend® SF PH4 (liquid)
Glutamine 250 mg/ml in SyrSpend® SF PH4 (liquid)
Levofloxacin 50 mg/ml in SyrSpend® SF PH4 (liquid)
Metoprolol tartrate 10 mg/ml in SyrSpend® SF PH4 (liquid)
Nitrofurantoin 2 - 10 mg/ml in SyrSpend® SF PH4 (liquid)
Ondansetron HCl 0.8 mg/ml in SyrSpend® SF PH4 (liquid)
Oxandrolone 3 mg/ml in SyrSpend® SF PH4 (liquid)
Pregabalin 20 mg/ml in SyrSpend® SF PH4 (liquid)
Riboflavin (vit. B2) 10 mg/ml in SyrSpend® SF PH4 (liquid)

Visit our Compounding Matters formulation database for over 200 other oral liquid formulations with our Syrspend® SF vehicles.